Skip directly to search Skip directly to A to Z list Skip directly to site content

Cholinesterase Inhibitors: Including Insecticides and Chemical Warfare Nerve Agents
Table of Contents

Course: WB 1098
CE Original Date: October 16, 2007
CE Renewal Date: October 16, 2010
CE Expiration Date: October 16, 2012
Download Printer-Friendly version [PDF - 1.88 MB]

Previous Section Next Section
Cover Page
Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome

How to Use This Course
Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome
Management Strategy 1: Prevention of Secondary Exposure

Initial Check
Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome
Management Strategy 2: Supportive Care

Part 1: Community Preparedness for Mass Casualty Events Involving Cholinesterase Inhibitors
Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome
Management Strategy 3: Medications

Part 2: What are cholinesterase inhibitors?
Part 4 - Section 11
Management Strategy 3: Medications
Atropine

Part 3: What types of pathology do cholinesterase inhibitors cause?
Part 4 - Section 11
Management Strategy 3: Medications
2-PAM (2-Pyridine Aldoxime Methylchloride) (Pralidoxime)

Part 4: The Cholinergic Toxidrome
Section 1: What is the Cholinergic Toxidrome?

Part 4 - Section 11
Management Strategy 3: Medications
Diazepam

Part 4: The Cholinergic Toxidrome
Section 2: Nicotinic Acetylcholine Receptors

Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome
Antidote Stocking (Optional Reading)

Part 4: The Cholinergic Toxidrome
Section 3: Muscarinic Acetylcholine Receptors

Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome
Syrup of Ipecac, Gastric Lavage, Cathartics, and Activated Charcoal

Section 4: Clinical Findings in Cholinesterase Inhibitor Toxicity Are Due to a Mixture of Nicotinic and Muscarinic Effects
Part 4: The Cholinergic Toxidrome
Section 12: Public Health and Medico-Legal Issues

Part 4: The Cholinergic Toxidrome
Section 5: Signs and Symptoms by Route of Exposure and Chemical Structure of the Involved Cholinesterase Inhibitor (Optional Reading)

Part 5: The Intermediate Syndrome
Part 4: The Cholinergic Toxidrome
Section 6: Effects on Routine Laboratory Tests

Part 6: Organophosphate-Induced Delayed Neuropathy (OPIDN)
Part 4: The Cholinergic Toxidrome
Section 7: Differential Diagnosis of the Cholinergic Toxidrome

Part 7: Organophosphorus Ester-Induced Chronic Neurotoxicity (OPICN)
Part 4: The Cholinergic Toxidrome
Section 8: Signs and Symptoms: Differences in Pediatric Cases

Part 8: Other Issues Related to Cholinesterase Inhibitor Exposure
Part 4: The Cholinergic Toxidrome
Section 9: Importance of the Exposure History

Assessment and Posttest Instructions
Part 4: The Cholinergic Toxidrome
Section 10: Laboratory Assessment of the Cholinergic Toxidrome Red Blood Cell (RBC) and Serum Cholinesterase

Literature Cited
Part 4: The Cholinergic Toxidrome
Section 10: Laboratory Assessment of the Cholinergic Toxidrome Direct Measurement of Cholinesterase Inhibitors and Their Metabolic Byproducts

 
Previous Section Next Section
 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO

A-Z Index

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #